TIDMGSK

RNS Number : 5160U

GlaxoSmithKline PLC

06 April 2021

Issued: 6 April 2021, London UK

GSK announces Dr Anne Beal to join the Board as Non-Executive Director

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that Dr Anne Beal will join the Board of the Company as a Non-Executive Director with effect from 6 May 2021.

On joining the Board, Dr Beal will become a member of the Corporate Responsibility Committee (the 'Committee') which provides important oversight of the Company's Trust agenda including policies towards access to medicines, global health, inclusion and diversity and environmental sustainability. Dr Beal will succeed Lynn Elsenhans as Chair of the Committee after the 2022 Annual General Meeting. Ms Elsenhans has agreed to remain on the Board for a further year to facilitate an orderly transition to Dr Beal's leadership of the Committee.

Dr Beal will bring to GSK extensive healthcare experience as a physician and entrepreneur combined with a passion for patient advocacy. She is a recognised health policy expert in the development of global and national programmes for improving healthcare access for all patient groups and in ensuring the voice of patients is reflected in research programmes.

Commenting on the changes, Sir Jonathan Symonds, Chairman of GSK said: "I am delighted to welcome Anne to GSK. Acting responsibly is an integral part of how successful modern businesses deliver for a wide range of stakeholders including investors. That's why the work of the Corporate Responsibility Committee is critical to the success of GSK. Anne's expertise and experience will be a valuable addition to GSK and to the leadership of the Committee. I would like to thank Lynn for her service to the Company over the last nine years and to agreeing to stay on to ensure a smooth transition to Anne."

Dr Beal is founder and CEO of AbsoluteJOI Skincare and a member of the Board of AcademyHealth. Prior to her current roles, Dr Beal spent six years at Harvard Medical School and Massachusetts General Hospital, where she was an instructor in paediatrics and has also held leadership roles at the Commonwealth Fund and the Aetna Foundation. In addition, Dr Beal was previously Deputy Executive Director and Chief Engagement Officer for The Patient-Centered Outcomes Research Institute in the U.S. and Chief Patient Officer and Global Head of Patient Solutions at Sanofi.

She holds a B.A. from Brown University, an M.D. from Cornell University Medical College, and an M.P.H. from Columbia University.

Notes

 
 1.   The appointment of Dr Anne Beal was made by the Board on 
       the recommendation of the Nominations & Corporate Governance 
       Committee. 
 2.   The Board has determined that Dr Beal will be an independent 
       Non-Executive Director on appointment in accordance with 
       the UK Corporate Governance Code. 
 3.   Dr Beal will receive the standard basic fee for a Non-Executive 
       Director of GBP95,000 per annum. She will receive a further 
       payment of GBP40,000 per annum when she succeeds Ms Elsenhans 
       as Chair of the Corporate Responsibility Committee. 
 
       Dr Beal will be required to invest at least 25% of her fees 
       in GSK shares that should be held until her retirement from 
       the Board. 
 4.   Membership of other Committees will be determined in due 
       course. 
 5.   Dr Beal does not have a service contract. She has a letter 
       of appointment which may be viewed by contacting the Company 
       Secretary at the Company's registered office. 
 6.   There are no additional details to disclose in respect of 
       Dr Beal's appointment under Listing Rule 9.6.13R. 
 7.   From 6 May 2021 the Board of GSK will comprise: 
      Sir Jonathan Symonds   Non-Executive Chairman 
       Emma Walmsley          Chief Executive Officer 
       Iain Mackay            Chief Financial Officer 
       Dr Hal Barron          Chief Scientific Officer and President, 
       Vindi Banga            R&D 
       Charles Bancroft       Senior Independent Non-Executive Director 
       Dr Anne Beal           Independent Non-Executive Director 
       Dr Vivienne Cox        Independent Non-Executive Director 
       Lynn Elsenhans         Independent Non-Executive Director 
       Dr Jesse Goodman       Independent Non-Executive Director 
       Dr Laurie Glimcher     Independent Non-Executive Director 
       Urs Rohner             Independent Non-Executive Director 
                              Independent Non-Executive Director 
 
        As previously announced, Charles Bancroft has succeeded 
        Judy Lewent as Chair of the Audit & Risk Committee following 
        approval of GSK's 2020 Annual Report. Judy will not stand 
        for re-election to the Board at GSK's Annual General Meeting 
        on 5 May 2021. 
 
        Lynn Elsenhans will stand for re-election at the AGM and 
        remain on the Board for a further year to facilitate a smooth 
        handover to Dr Beal.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us .

 
 GSK enquiries: 
 Media enquiries:   Simon Steel         +44 (0) 20 8047   (London) 
                                         5502 
                    Madeleine Breckon   +44 (0) 7880      (London) 
                                         040 329 
                    Kristen Neese       +1 804 217 8147   (Philadelphia) 
 
 Analyst/Investor   James Dodwell       +44 (0) 20 8047   (London) 
  enquiries:                             2406 
                    Sonya Ghobrial      +44 (0) 7392      (Consumer) 
                                         784784 
                    Mick Readey         +44 (0) 7990      (London) 
                                         339653 
                    Jeff McLaughlin     +1 215 751 7002   (Philadelphia) 
                    Frannie DeFranco    +1 215 751 4855   (Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020 and any impacts of the COVID-19 pandemic.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAZZGGDMVRGMZM

(END) Dow Jones Newswires

April 06, 2021 09:30 ET (13:30 GMT)

Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Gsk Charts.